Rebecca W.  Rimel net worth and biography

Rebecca Rimel Biography and Net Worth

Rebecca W. Rimel serves as a director of BD (Becton, Dickinson and Company), a global medical technology company headquartered in Franklin Lakes, New Jersey. Rimel has been a member of the board since 2012.

From 1994 until her retirement in July 2020, Rimel served as president and chief executive officer of The Pew Charitable Trusts, a public charity that works to improve public policy and inform the public on issues and trends. Prior thereto, she served as Assistant Professor in the Department of Neurosurgery at the University of Virginia Hospital and also as Head Nurse of its medical center emergency department. Rimel also is a director of BioTelemetry, Inc., a director/trustee of various DWS mutual funds, and a member of the Board of Trustees of The Bridgespan Group.

Rimel brings executive leadership and extensive experience in public policy and advocacy, particularly in the area of healthcare. She also offers the perspective of someone with a strong background in the healthcare field.

What is Rebecca W. Rimel's net worth?

The estimated net worth of Rebecca W. Rimel is at least $27.41 million as of May 31st, 2018. Ms. Rimel owns 120,375 shares of Becton, Dickinson and Company stock worth more than $27,406,980 as of December 21st. This net worth approximation does not reflect any other investments that Ms. Rimel may own. Learn More about Rebecca W. Rimel's net worth.

How do I contact Rebecca W. Rimel?

The corporate mailing address for Ms. Rimel and other Becton, Dickinson and Company executives is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. Becton, Dickinson and Company can also be reached via phone at (201) 847-6800 and via email at [email protected]. Learn More on Rebecca W. Rimel's contact information.

Has Rebecca W. Rimel been buying or selling shares of Becton, Dickinson and Company?

Rebecca W. Rimel has not been actively trading shares of Becton, Dickinson and Company during the last ninety days. Learn More on Rebecca W. Rimel's trading history.

Who are Becton, Dickinson and Company's active insiders?

Becton, Dickinson and Company's insider roster includes Simon Campion (EVP), Alexandre Conroy (EVP), Christopher DelOrefice (Exec. VP & CFO ), Claire Fraser (Director), John Gallagher (VP), Michael Garrison (EVP), Roland Goette (EVP), David Hickey (EVP), Patrick Kaltenbach (EVP), Samrat Khichi (EVP), Betty Larson (EVP), James Lim (EVP), Thomas Polen, Jr. (Insider), Rebecca Rimel (Director), and Thomas Spoerel (VP). Learn More on Becton, Dickinson and Company's active insiders.

Are insiders buying or selling shares of Becton, Dickinson and Company?

During the last year, insiders at the medical instruments supplier sold shares 8 times. They sold a total of 16,856 shares worth more than $3,864,918.44. The most recent insider tranaction occured on December, 19th when EVP Michael David Garrison sold 2,838 shares worth more than $633,810.54. Insiders at Becton, Dickinson and Company own 0.3% of the company. Learn More about insider trades at Becton, Dickinson and Company.

Information on this page was last updated on 12/19/2024.

Rebecca W. Rimel Insider Trading History at Becton, Dickinson and Company

See Full Table

Rebecca W. Rimel Buying and Selling Activity at Becton, Dickinson and Company

This chart shows Rebecca W. Rimel's buying and selling at Becton, Dickinson and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Becton, Dickinson and Company Company Overview

Becton, Dickinson and Company logo
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Read More

Today's Range

Now: $227.68
Low: $223.51
High: $229.31

50 Day Range

MA: $229.88
Low: $220.02
High: $243.75

2 Week Range

Now: $227.68
Low: $218.75
High: $249.89

Volume

3,083,279 shs

Average Volume

1,490,132 shs

Market Capitalization

$65.83 billion

P/E Ratio

38.33

Dividend Yield

1.83%

Beta

0.41